Drug Profile
Research programme: ulcerative colitis therapy - SIDR
Latest Information Update: 04 Aug 2004
Price :
$50
*
At a glance
- Originator Strathclyde Institute for Drug Research
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 04 Aug 2004 Discontinued - Preclinical for Ulcerative colitis in United Kingdom (unspecified route)
- 29 Oct 1999 This programme is available for licensing (http://www.sidr.org)
- 20 Jul 1999 New profile